Nearly all men with non-metastatic castration-resistant prostate cancer (nmCRPC) received the full planned dose of Nubeqa (darolutamide) tablets while participating in the ARAMIS Phase 3 trial, and few required dose adjustments or discontinued treatment, according to a new ad-hoc analysis of the study. Findings from this analysis were recently presented in an e-poster, titled “Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial,” at…
You must be logged in to read/download the full post.
The post Most nmCRPC Patients Can Safely Take Full Dose of Nubeqa, Trial Analysis Shows appeared first on BioNewsFeeds.